Drug intelligence / Profile preview

anbainuo + methotrexate

Development stage: Unknown
Lead developer: Zhejiang Hisun Pharmaceutical
Modality: Small Molecules
Administration: Subcutaneous, Oral

Overview

A combination therapy consisting of Anbainuo (a biosimilar of etanercept) and methotrexate. This combination is used primarily for treating moderate to severe rheumatoid arthritis in patients who have had an inadequate response to methotrexate alone. It has demonstrated increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs (DMARDs).

Other names: ABN + MTX

Targets

DHFR (Dihydrofolate reductase)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on anbainuo + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anbainuo + methotrexate.

Explore the full profile